BioAtla (BCAB) Receivables - Other (2025 - 2026)

BioAtla's (BCAB) quarterly Receivables - Other came in at $4.5 million in Q1 2026, up 45.16% quarter-over-quarter from $3.1 million in Q4 2025.

BioAtla (BCAB) Receivables - Other (2025 - 2026) Analysis & Trends

BioAtla's Receivables - Other history runs 2 years deep, the most recent figure standing at $4.5 million for Q1 2026.

On a quarterly basis, Receivables - Other changed N/A year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $4.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.1 million, changed N/A from the prior year.
Receivables - Other rose to $4.5 million in Q1 2026 per BCAB's latest filing, from $3.1 million in the prior quarter.
Across five years, Receivables - Other topped out at $4.5 million in Q1 2026 and bottomed at $3.1 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,921.77 Bn	66,921.49 Bn	-
2	Nanobiotix	1,933.35 Bn	1,933.29 Bn	-
3	Akari Therapeutics	1,063.56 Bn	1,063.56 Bn	-
4	BeOne Medicines	468.54 Bn	463.75 Bn	1.35 Bn
5	Vertex Pharmaceuticals	123.45 Bn	116.20 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.42 Bn	61.67 Bn	3.31 Bn
7	Belite Bio	63.57 Bn	63.57 Bn	-
8	Argenx Se	55.83 Bn	50.65 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.75 Bn	34.74 Bn	959.66 Mn
10	BioAtla	5.20 Mn	5.20 Mn	-

Download Data